Quantcast

Industry news that matters to you.  Learn more

bioTheranostics’ Breast Cancer Index Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards

bioTheranostics, Inc., a leading genomic solutions provider for cancer, recently announced that its Breast Cancer Index molecular test has been selected as a finalist in the Life Sciences—Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT. CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County, continues its 27-year tradition of honoring San Diego’s leaders of innovation and groundbreaking new products with the annual award.

bioTheranostics Awarded Medicare Coverage for Breast Cancer Index Molecular Test

bioTheranostics, Inc., a leader in molecular diagnostics for cancer, recently announced that its Breast Cancer Index test has been awarded Medicare coverage. The Centers for Medicare and Medicaid Services posted a positive coverage and reimbursement policy after evaluation by Palmetto GBA, the Medicare administrator responsible for the MolDx molecular diagnostic technology assessment program.

bioTheranostics Receives Approval to Perform Breast Cancer Index Testing for Patients in State of New York

bioTheranostics, Inc., a leading provider of genomic solutions for cancer patients, recently announced that the New York State Department of Health has approved the use of its Breast Cancer IndexSM, a molecular test that determines risk of early and late recurrence and benefit from extended endocrine therapy in patients with early stage, estrogen receptor-positive breast cancer. With this approval, bioTheranostics can now perform Breast Cancer Index testing on tissue samples from patients in New York State.

bioTheranostics Signs Agreement with National PPO Network Prime Health Services

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, recently signed a contract with Prime Health Services, Inc., a national preferred provider organization network, to cover the company’s genomic tests for breast cancer patients and patients with metastatic disease.

bioTheranostics Announces Contract with Three Rivers Provider Network

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, recently announced a contract with Three Rivers Provider Network for coverage of the company’s testing services, including CancerTARGET ID for accurate diagnosis of metastatic cancer, and Breast Cancer Index, which predicts risk of recurrence of early stage, estrogen receptor-positive breast cancer.